Navigation Links
DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform
Date:11/8/2016

HOUSTON, Nov. 8, 2016 /PRNewswire/ -- DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced it has entered into an exclusive license agreement with the University of Florida, Gainesville to develop a novel oncolytic virus platform.  The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers. 

A major advantage of the myxoma virus is its ability to attach to T lymphocytes and other white blood cells, which are then delivered to the patient to trigger tumor cell killing and antitumor immunity.  Myxoma virus can be armed with multiple immune stimulatory genes, a feature shared by other large DNA viruses such as herpes simplex and adenovirus.   

"The myxoma virus has unique properties for attacking cancer," said CEO Frank Tufaro, Ph.D. "We think this technology platform provides a new modality for delivery of a potent oncolytic virus to tumors by co-administering it along with T cells.  We look forward to testing this 'Trojan horse' strategy in the clinic."

"The myxoma virus is a novel oncolytic candidate that does not infect normal human cells but has a unique ability to identify the damaged signaling pathways found in the majority of human cancers; thus, resulting in productive infections in the patient's cancer cells," stated Grant McFadden, Ph.D., Professor in the Department of Molecular Genetics & Microbiology at the University of Florida, College of Medicine.

About DNAtrix
DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic virus being studied in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.DNAtrix.com.

Contact 
DNAtrix
Imran Alibhai, Ph.D.
S.V.P. Business Development
ialibhai@dnatrix.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dnatrix-licenses-myxoma-virus-for-new-immunotherapy-platform-300359303.html


'/>"/>
SOURCE DNAtrix
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. DNAtrix Collaborators Present Data on a Novel Oncolytic Adenovirus Expressing OX40 Ligand that Promotes Antitumor Immunity
2. DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial
3. DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus
4. New Colombia Resources Sannabis Subsidiary Announces Filing for Medical Marijuana Licenses With the Ministry of Justice in order to Export Products
5. Enterome In-licenses Novel Compounds From Vertex Pharmaceuticals to Treat Microbiome-related Inflammatory Bowel Diseases
6. Oxford BioTherapeutics Licenses Nerviano Medical Sciences Drug-Linker Technology to Develop Novel Antibody Drug Conjugates
7. Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetriks
8. ATCC Licenses CRISPR/Cas9 Technology from the Broad Institute
9. Spero Therapeutics Licenses Dihydrofolate Reductase Inhibitors from Promiliad Biopharma to Enhance Anti-Infective Pipeline
10. Variant Pharmaceuticals Licenses Worldwide Rights To Asset Targeted to Treat Rare Diseases From L&F Research
11. ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... Shelton, CT (PRWEB) , ... October 13, 2017 , ... ... and long-term care services, staged a mock evacuation of the facility as part of ... Department, Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well ...
(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
Breaking Medicine News(10 mins):